RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
NRIX - Nurix Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.64
DETAILS
HIGH:
$45.00
LOW:
$23.00
MEDIAN:
$34.00
CONSENSUS:
$33.64
UPSIDE:
45.50%
Stock News
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $0.52 per share a year ago.
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nurix Stock Up 29% in a Month: Here's What You Should Know
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nurix Therapeutics Deal With Roche Is Worth Betting On
Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validate NRIX's bexobrutideg and its potential as a broader platform in the long term. NRIX's bexobrutideg is easily their main value driver, and after NRIX's recent equity raises and deal with Roche, it looks like they should have enough runway for the foreseeable future.
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median progression-free survival of 22.1 months and an objective response rate of 83% in heavily pretreated relapsed/refractory CLL/SLL patients Bexobrutideg was well tolerated with longer follow-up demonstrating a safety profile consistent with prior disclosures Responses observed across difficult-to-treat patient subgroups, including high-risk features, BTK resistance mutations and CNS involvement Data to be presented at the 2026 European Hematology Association (EHA) Congress BRISBANE, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced updated clinical data from the Company's ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL).
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and secures a transformative $2.3B global partnership with Roche. Bexobrutideg demonstrates superior efficacy over JAYPIRCA, achieving an 83% ORR and 22.1 months mPFS in heavily pretreated r/r CLL patients at the 600 mg dose. The Roche deal brings $700M upfront, potential total value of $2.3B in milestones, and enables expansion into immunology and neurology, notably multiple sclerosis and chronic spontaneous urticaria.
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Nurix Therapeutics, Inc. (NRIX) Discusses Strategic Collaboration for Development and Commercialization of Bexobrutideg for BTK-Mediated Diseases Transcript
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
Roche Holding AG (RHHBY) has agreed to pay Nurix Therapeutics (NRIX) as much as $2.3 billion for rights to bexobrutideg, an experimental pill targeting certain
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
This Biotech Stock Is Up 11% on $2.3 Billion Roche Deal for Blood Cancer Drug
Nurix Therapeutics strikes an agreement with Roche to commercialize its lead asset, bexobrutideg.
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
Nurix Therapeutics stock bounded of its 50-day line Monday after inking a deal with Roche for its BTK-degrading drug, bex-deg.
Nurix Therapeutics Stock Pops on Roche Partnership
Nurix Therapeutics Inc (NASDAQ:NRIX) stock is up 15.7% to trade at $16.94, after the biotech company announced a collaboration and licensing agreement with Roche for blood cancer treatment bexobrutideg.
Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market
Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock is up during Monday's premarket session as the company collaborates with Roche Holdings AG (OTC:RHHBY) to co-develop and co-commercialize bexobrutideg, an investigational Bruton's Tyrosine Kinase (BTK) degrader.
Roche enters $2 billion cancer drug agreement with Nurix Therapeutics
Swiss pharmaceutical giant Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics of up to $2.3 billion, the company said on Monday.
Roche Enters $2.3 Billion Blood-Cancer Drug Deal With Nurix Therapeutics
The Swiss drugmaker said it would pay Nurix $700 million upfront, while development costs would be split 60-40, with Roche taking the larger share.
Price Targets
Nurix (NRIX) PT Raised to $34 at Mizuho
$34.00
(was $23.06)
Joseph Catanzaro
·
Mizuho Securities
Nurix Therapeutics price target raised to $33 from $30 at RBC Capital
$33.00
(was $22.33)
RBC Capital
Nurix Therapeutics price target raised to $34 from $32 at Truist
$34.00
(was $23.05)
Gregory Renza
·
Truist Financial
Nurix Therapeutics price target raised to $40 from $34 at Stifel
$40.00
(was $24.69)
Stifel Nicolaus
Nurix (NRIX) PT Raised to $34 at H.C. WainwrightMember Login
$34.00
(was $24.69)
H.C. Wainwright
Nurix Therapeutics price target raised to $33 from $26 at Baird
$33.00
(was $17.12)
Robert W. Baird
UBS Reiterates Buy Rating on Nurix (NRIX)
$23.00
(was $15.07)
David Dai
·
UBS
Nurix Therapeutics price target raised to $32 from $30 at BTIG
$32.00
(was $15.64)
Jeet Mukherjee
·
BTIG
Nurix Therapeutics price target raised to $32 from $30 at Truist
$32.00
(was $15.64)
Truist Financial
Nurix Therapeutics price target raised to $45 from $41 at Jefferies
$45.00
(was $15.56)
Roger Song
·
Jefferies
Nurix Therapeutics price target raised to $34 from $26 at Needham
$34.00
(was $15.89)
Needham
Nurix Therapeutics price target lowered to $28 from $29 at Wells Fargo
$28.00
(was $16.24)
Wells Fargo
Nurix Therapeutics price target raised to $35 from $33 at Stifel
$35.00
(was $18.55)
Stifel Nicolaus
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo
$29.00
(was $17.87)
Derek Archila
·
Wells Fargo
Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright
$32.00
(was $17.87)
H.C. Wainwright
Nurix Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
$36.00
(was $18.49)
Morgan Stanley
Nurix Therapeutics price target raised to $31 from $28 at H.C. Wainwright
$31.00
(was $19.55)
Robert Burns
·
H.C. Wainwright
Nurix Therapeutics price target raised to $30 from $27 at BTIG
$30.00
(was $21.47)
BTIG
Nurix Therapeutics assumed with a Buy at Truist
$30.00
(was $17.18)
Truist Financial
Nurix Therapeutics price target lowered to $28 from $33 at H.C. Wainwright
$28.00
(was $11.93)
H.C. Wainwright